Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.
We here present the study results of 21 HIV-1 infected children who were treated with indinavir plus low-dose ritonavir and two nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. Although this q12h HAART regimen had potent antiretroviral activity, it was frequently associated with side effects and discontinuation of therapy.
Fraaij
P L A
PL
Dept. of Pediatrics, Erasmus MC-Sophia Children's Hospital, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands. p.fraaij@erasmusmc.nl
Verweel
G
G
van Rossum
A M C
AM
Hartwig
N G
NG
Burger
D M
DM
de Groot
R
R
D000293:Adolescent; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019469:Indinavir / Q000009:adverse effects; D007223:Infant; D008297:Male; D019438:Ritonavir / Q000009:adverse effects
D017320:HIV Protease Inhibitors; D019469:Indinavir; D019438:Ritonavir